Slide 1: Investor Presentation March 2012
For personal use only Investor Presentation March 2012 DISCLAIMER The release, publication or distribution of this presentation in certain jurisdictions may be restricted by law and therefore persons in such jurisdictions into which this presentation is released, published or distributed should info
Slide 2: Managing for Growth / Strategic Vision
MANAGING FOR GROWTH For personal use only • Who is Clover • What happened in the past year • Clover‟s competitive position and challenges • Clover‟s strategy for the current year • The year so far 3 STRATEGIC VISION Clover Corporation seeks to: • Identify, develop and commercialise speciality functi
Slide 3: Company Description / Trading Update & Outlook FY2012
COMPANY DESCRIPTION For personal use only • Focus on two business units: – Clover Corporation focuses on innovation & obtaining the optimal return from proprietary technology – Nu-Mega Ingredients commercialises proprietary ingredient delivery and encapsulation technology in targeted value added mar
Slide 4: Sales Revenue +27.8% in the First Half FY2012
SALES REVENUE +27.8% IN THE FIRST HALF FY2012 For personal use only million ($) Normalised period for 1 August to 31 January 20 18 16 14 12 10 8 6 4 2 0 FP11 FP11 (normalised) FY12 Sales Revenue * Normalised results are non-statutory measures and represent results from continuing operations. Expense
Slide 5: Key Company Developments / Overview of Nu-Mega Products
KEY COMPANY DEVELOPMENTS For personal use only 2007-2011 • Nu-Mega Ingredients 100% subsidiary of Clover 2002-2007 Corporation • 2008 - New Innovation & • Clover Corp JV with Food Sales facility in Brisbane Spectrum = Nu-Mega • Development of the Ingredients innovations program • Uses encapsulated t
Slide 6: Summary of Financial Performance
SUMMARY OF FINANCIAL PERFORMANCE For personal use only FP2011 (13 months) FY2010 FY2009 FY2008 FY2007 Shares on issue 165.2 m 165.2 m 165.2 m 165.2 m 165.2 m Total contributed equity $32.9 m $32.9 m $28.3 m $27.0 m $23.7 m $48.7 m $66.1 m $33.0m $29.7m $18.2m Market capitalisation (as at 21/11/11) (
Slide 7: Continued Focus on Growth Markets & Value Added Products
CONTINUED FOCUS ON GROWTH MARKETS & VALUE ADDED PRODUCTS For personal use only FP2011 Geographic • Nu-Mega activities in the infant formula area has resulted in increases in sales Australia/New Zealand 16% during FP2011 of; Asia 73% – Americas +32% – Europe +65% Europe 7% • In FY2012 sales increasin
Slide 8: Competitive Strengths – A Culture of Commercial Innovation
COMPETITIVE STRENGTHS – A CULTURE OF COMMERCIAL INNOVATION For personal use only • Clover‟s core strengths; – Growing share in value added markets – Proprietary & patented technology – Commercial focus with high returns on R&D – High quality products & excellent reputation with clients – Dedicated a
Slide 9: Innovation Leads to New Products & Revenues
INNOVATION LEADS TO NEW PRODUCTS & REVENUES For personal use only Company Form Bioactive rights Application TECH 1 (OWNED) ENCAPSULATION Omega 3 lipids Infant formula # Carbohydrate based encapsulation system for foods. Infant formula / TECH 2 (LICENSED) ENCAPSULATION Omega 3 &/or 6 lipids Functiona
Slide 10: Thank You
For personal use only THANK YOU Questions? 19 10